View All HCPCS Sections

• M0001

  Advancing cancer care mips value pathways

• M0002

  Optimal care for kidney health mips value pathways

• M0003

  Optimal care for patients with episodic neurological conditions mips value pathways

• M0004

  Quality care for patients with neurological conditions mips value pathway

• M0005

  Value in primary care mips value pathway

• M0010

  Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services

• M0064

  Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders

• M0075

  Cellular therapy

• M0076

  Prolotherapy

• M0100

  Intragastric hypothermia using gastric freezing

• M0201

  Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home

• M0220

  Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring

• M0221

  Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

• M0222

  Intravenous injection, bebtelovimab, includes injection and post administration monitoring

• M0223

  Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

• M0224

  Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring

• M0233

  Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose

• M0234

  Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

• M0235

  Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose

• M0236

  Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose

• M0237

  Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose

• M0238

  Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

• M0239

  Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring

• M0240

  Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses

• M0241

  Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses

• M0243

  Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring

• M0244

  Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

• M0245

  Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring

• M0246

  Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency

• M0247

  Intravenous infusion, sotrovimab, includes infusion and post administration monitoring

• M0248

  Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

• M0249

  Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose

• M0250

  Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

• M0300

  Iv chelation therapy (chemical endarterectomy)

• M0301

  Fabric wrapping of abdominal aneurysm

• M1000

  Pain screened as moderate to severe

• M1001

  Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician

• M1002

  Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given

• M1003

  Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy

• M1004

  Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)

• M1005

  Tb screening not performed or results not interpreted, reason not given

• M1006

  Disease activity not assessed, reason not given

• M1007

  >=50% of total number of a patient's outpatient ra encounters assessed

• M1008

  <50% of total number of a patient's outpatient ra encounters assessed

• M1009

  Discharge/discontinuation of the episode of care documented in the medical record

• M1010

  Discharge/discontinuation of the episode of care documented in the medical record

• M1011

  Discharge/discontinuation of the episode of care documented in the medical record

• M1012

  Discharge/discontinuation of the episode of care documented in the medical record

• M1013

  Discharge/discontinuation of the episode of care documented in the medical record

• M1014

  Discharge/discontinuation of the episode of care documented in the medical record

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.